← Back to Clinical Trials
Recruiting NCT07358910

NCT07358910 Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07358910
Status Recruiting
Phase
Sponsor Institut Pasteur du Cambodge
Condition Dengue
Study Type OBSERVATIONAL
Enrollment 10,000 participants
Start Date 2025-12-18
Primary Completion 2026-04-16

Eligibility & Interventions

Sex All sexes
Min Age 2 Years
Max Age 75 Years
Study Type OBSERVATIONAL
All Conditions
Dengue Chikungunya Zika Virus Infection Japanese Encephalitis West Nile Virus Tick-borne Encephalitis (TBE) Severe Fever With Thrombocytopenia Syndrome Nipah Virus Infection Hantavirus Infections Hepatitis E Brucellosis Q Fever Leptospirosis Melioidosis Influenza A and B Malaria Yellow Fever Mayaro Fever Usutu Virus Infection Oropouche Fever Rift Valley Fever Arenavirus Infections Measles Mumps Rubella Human Papilloma Virus (HPV) Rotavirus Disease Pertussis Diphteria Tetanus Varicella Hepatitis A Norovirus Infections Enterovirus Adenovirus Rhinovirus Parvovirus Respiratory Syncytial Virus (RSV) Cytomegalovirus Epstein Barr Virus Salmonella Typhi Vibrio Cholerae Legionella Pneumophila Pneumonia Mycoplasma Chlamydia Lymphatic Filariasis Toxoplasma Gondii Giardiasis Entamoeba Histolytica Leishmaniasis Strongyloides Stercoralis Infection Ascaris Lumbricoides Trichuris Trichiura Clonorchis Sinensis Opisthorchis Viverrini Schistosomiasis Streptococcus Pneumoniae Meningitis

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 10,000 participants in total. It began in 2025-12-18 with a primary completion date of 2026-04-16.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

RACSMEI addresses the high burden of infectious diseases in low- and middle-income countries, including Cambodia, where limited surveillance and laboratory capacity often obscure etiologies and transmission dynamics. This knowledge gap hinders the design of effective prevention and control strategies. RACSMEI will improve understanding across multiple pathogens using a multidisciplinary One Health approach. We will answer key questions on burden, ecology, transmission and population immune status to inform targeted and culturally appropriate interventions. The project combines a nationally representative One Health survey, social-science methods, and multiplex, diverse diagnostics to efficiently test for 57 priority pathogens, including zoonotic and vector-borne agents, vaccine-preventable and elimination-targeted diseases, enteric, respiratory, and environmentally transmitted pathogens and selected neglected tropical diseases and parasites relevant to Cambodia. Mathematical modelling will reconstruct and forecast transmission dynamics and assess the potential impact of future public-health strategies. By integrating intersectoral data and innovative methods, RACSMEI will generate actionable evidence for public-health authorities, support precision One Health interventions, and help reduce disease burden in affected communities. The project also aims to ensure the transferability of methods and insights to other countries facing similar challenges.

Eligibility Criteria

Inclusion Criteria: * Residency in the village for more than 6 months; * Age between 2 and 75 years old at the time of inclusion; * For adults: provision of written consent; * For children aged 2-17 years: written parental consent form, verbal assent from children aged 13-17 years; Exclusion Criteria: * Unable to understand or consent; * Under guardianship or deprived of liberty; * Medical conditions that impede survey participation; * Refusal to participate in the study.

Contact & Investigator

Central Contact

Claude Flamand, Ph.D.

✉ cflamand@pasteur-kh.org

📞 +855012333650

Principal Investigator

Claude Flamand, Ph.D.

PRINCIPAL INVESTIGATOR

Institut Pasteur du Cambodge

Frequently Asked Questions

Who can join the NCT07358910 clinical trial?

This trial is open to participants of all sexes, aged 2 Years or older, up to 75 Years, studying Dengue. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07358910 currently recruiting?

Yes, NCT07358910 is actively recruiting participants. Contact the research team at cflamand@pasteur-kh.org for enrollment information.

Where is the NCT07358910 trial being conducted?

This trial is being conducted at Phnom Penh, Cambodia.

Who is sponsoring the NCT07358910 clinical trial?

NCT07358910 is sponsored by Institut Pasteur du Cambodge. The principal investigator is Claude Flamand, Ph.D. at Institut Pasteur du Cambodge. The trial plans to enroll 10,000 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology